Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Disease & Drugs

Clinical Trials

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Clinical Trials

1,156 stories · every one Fact-Checked
Roche's obinutuzumab anti-CD20 therapy receives positive CHMP recommendation for systemic lupus erythematosus.Clinical TrialsRoche Secures Positive CHMP Recommendation for Obinutuzumab in SLERoche’s obinutuzumab has received a positive CHMP recommendation for systemic lupus erythematosus in the EU. The recommendation follows Phase III ALLEGORY results showing improved disease activity, sustained glucocorticoid…13 Nov 2026 · 4 min read
Fact-Checked
Merck belzutifan and lenvatinib combination receives positive EU CHMP opinion for previously treated advanced clear-cell renal cell carcinoma.Clinical TrialsMerck Gains EU CHMP Backing for Belzutifan in Advanced RCCMerck’s belzutifan plus lenvatinib combination receives a positive EU CHMP opinion for previously treated advanced clear-cell renal cell carcinoma.13 Nov 2026 · 3 min read
Fact-Checked
Zai Lab's investigational bispecific antibody ZL-1503 targeting IL-13 and IL-31Rα pathways in atopic dermatitis.Clinical TrialsZai Lab’s ZL-1503 Sustains Atopic Dermatitis Biomarker Suppression Through Week 12Zai Lab’s investigational bispecific antibody ZL-1503 demonstrated sustained IL-13 pathway biomarker suppression through Week 12 following a single intravenous dose.13 Nov 2026 · 5 min read
Fact-Checked
BioCryst ORLADEYO berotralstat real-world study showing reduced angioedema-related medical visits in patients with hereditary angioedema.Clinical TrialsBioCryst Reports Reduced Healthcare Utilization Across ORLADEYO StudiesBioCryst reported real-world evidence showing a 30% reduction in overall angioedema-related medical visits per patient-year among 78 patients with hereditary angioedema who switched to ORLADEYO (berotralstat).13 Nov 2026 · 4 min read
Fact-Checked
VTAMA (tapinarof) cream 1% evaluated for efficacy across atopic dermatitis subgroups in pooled Phase 3 ADORING trials.Clinical TrialsOrganon Reports Consistent Skin and Itch Improvements With VTAMAOrganon reported pooled post-hoc findings from the Phase 3 ADORING 1 and ADORING 2 trials showing consistent VTAMA (tapinarof) cream responses across atopic dermatitis subgroups.13 Nov 2026 · 4 min read
Fact-Checked
Regeneron's investigational NPR1-blocking antibody baloncibart evaluated in the Phase 2 PINNACLE trial for postural orthostatic tachycardia syndrome.Clinical TrialsRegeneron’s Baloncibart Delivers Sustained Heart Rate Benefits in POTSRegeneron’s investigational NPR1-blocking antibody baloncibart reduced orthostatic heart rate response through Day 29 in the Phase 2 PINNACLE trial.13 Nov 2026 · 5 min read
Fact-Checked
Ionis DAWNZERA (donidalorsen) two-year OASISplus study results showing sustained reduction in hereditary angioedema attacks.Clinical TrialsIonis Reports Long-Term Attack Reduction with DAWNZERA in HAEIonis Pharmaceuticals reported two-year OASISplus results showing a 95% reduction in hereditary angioedema attack rates with DAWNZERA in the open-label extension cohort.13 Nov 2026 · 4 min read
Fact-Checked
Pharvaris deucrictibant XR demonstrates 83% reduction in hereditary angioedema attacks in Phase 3 CHAPTER-3 trial.Clinical TrialsPharvaris Adds Long-Term HAE Prophylaxis and On-Demand Data for DeucrictibantPharvaris presented additional clinical findings for deucrictibant, including sustained HAE attack reduction over nearly 34 months in the CHAPTER-1 extension, improved quality-of-life outcomes and durable responses following on-demand…13 Nov 2026 · 4 min read
Fact-Checked
CuraSen Therapeutics CuraAX CST-3056 Phase 2a study showing improvements in standing blood pressure in patients with neurogenic orthostatic hypotension.Clinical TrialsCuraSen’s CuraAX Improves Standing Blood Pressure in Phase 2aCuraSen Therapeutics reports statistically significant, dose-dependent improvements in standing systolic blood pressure with CuraAX (CST-3056) in a 12-patient Phase 2a study of neurogenic orthostatic hypotension.12 Nov 2026 · 5 min read
Fact-Checked
Lilly Taltz and Zepbound combination therapy shows sustained improvements in psoriatic arthritis and weight reduction at Week 52.Clinical TrialsLilly’s Taltz-Zepbound Combination Delivers 43.7% ACR50 ResponseEli Lilly’s Phase 3b TOGETHER-PsA trial showed that combining Taltz (ixekizumab) with Zepbound (tirzepatide) improved psoriatic arthritis outcomes and weight reduction at Week 52 compared with Taltz alone.…12 Nov 2026 · 5 min read
Fact-Checked
Vasa Therapeutics VS-041 oral MMP inhibitor targeting cardiac fibrosis and fibroinflammation in heart failure with preserved ejection fraction.Clinical TrialsVasa Reports NT-proBNP Reduction With VS-041 in HFpEF TrialVasa Therapeutics reports positive Phase 1c results for VS-041, with reduced NT-proBNP after 28 days in patients with HFpEF.12 Nov 2026 · 4 min read
Fact-Checked
Beeline Medicines' investigational TLR7/8 inhibitor afimetoran demonstrates positive Phase 2 results in systemic lupus erythematosus.Clinical TrialsBeeline Reports Positive Phase 2 Results for Afimetoran in SLEBeeline Medicines reported positive Phase 2 results for afimetoran in systemic lupus erythematosus, with all three doses meeting the primary endpoint.12 Nov 2026 · 4 min read
Fact-Checked
Page 1 of 97